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Introduction
European public authorities struggle to maintain a high level of 
access to health care while restraining increases in expenditure 
associated with an ageing population and higher demand.1–4 
The recent global economic recession has put additional pres-
sure on public budgets.5,6
In 2008, Europe was affected by the financial crisis. As the 
recession in Europe continued, the effect was felt especially in 
southern European countries and Ireland in 2010 and 2011. 
Soon the problem of financial debt for individual European 
countries developed into a crisis in the Eurozone, which then 
became a high priority for the European Central Bank and 
the European Parliament. All countries were urged to imple-
ment cost-saving measures that affected public financing for 
health care.7
Recession, which is defined as two successive quarters 
of negative growth in gross domestic product (GDP), can 
have a detrimental effect on the health of the population 
because economic downturns are strongly associated with a 
decline in health-care utilization and a deterioration in health 
outcomes.8 For example, suicides and homicides increased 
among working-age men and women when unemployment 
rose rapidly during past recessions in Europe.9 In the current 
recession, the number of uninsured non-elderly Americans 
increased by 5.6 million between 2007 and 200910 and over a 
quarter of Americans reported reduced routine use of medi-
cal care.11 Over the same period, insurance policy deductibles 
and copayments for visits to physicians and for prescription 
medicines increased, leading to a greater cost burden for 
patients.12–14 Similar effects were seen in Greece. Studying the 
health effects of the economic crisis in the country it was found 
that patients had less access to care and preventive services 
and, consequently, faced higher risks of infection with sexu-
ally transmitted diseases.15 The World Health Organization 
examined the influence of the recession on expenditure on, 
and the sales and prices of, medicines between 2007 and 2009 
in 84 countries. It found that the economic recession had 
mixed effects and that the largest declines in medicine sales 
occurred in high-income countries and in Europe, particularly 
in the Baltic states.16
It has been shown that countries that were seriously af-
fected by the crisis, such as the Baltic countries, Greece, Por-
tugal and Spain, abruptly implemented several pharmaceutical 
policy measures between 2010 and 2011. This included price 
cuts, changes in reimbursement rates and the imposition of 
value-added tax on medicines.17 In other European countries, 
such as Italy, in which cost-containment measures were already 
in place when the crisis began, the implementation of planned 
policy changes was accelerated.18
Because different countries were affected differently by the 
recession and attempted to overcome budgetary constraints 
in different ways, we decided to analyse systematically how 
European pharmaceutical policies were affected by the reces-
Objective To identify pharmaceutical policy changes during the economic recession in eight European countries and to determine whether 
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sion by comparing changes in pharma-
ceutical pricing and reimbursement 
policies between economically stable 
and economically less stable countries. 
In addition, we investigated changes in 
the sale of pharmaceuticals in major 
therapeutic classes before and after the 
recession in these two types of countries. 
We expected that some of the cost-con-
tainment policies, such as those affecting 
out-of-pocket payments, would shift 
the financial burden of medicines onto 
patients and hypothesized that pharma-
ceutical sales would decline during this 




For this longitudinal study, we used data 
from two sources to derive information 
on pharmaceutical policies: (i) the Phar-
maceutical Pricing and Reimbursement 
Information Network (Austrian Health 
Institute, Vienna, Austria), which col-
lects information from experts in na-
tional pharmaceutical pricing and from 
authorities responsible for reimburse-
ment – the latter provide regular phar-
maceutical policy updates; and (ii) the 
PharmaQuery database (IMS Health, 
Philadelphia, United States of America), 
which contains data on pharmaceuti-
cal policies. In addition, we included 
information on policy changes reported 
in the published literature. We grouped 
policy changes into 6-month implemen-
tation periods from January 2008 until 
December 2011 and we categorized 
policy as relating to one of three main 
areas: (i) pricing; (ii) reimbursement; 
and (iii) generic drugs. Table 1 defines 
the policy measures in these three areas.
Quarterly pharmaceutical sales 
data for the period January 2006 to 
December 2011 were obtained from 
the IMS MIDAS (Multinational Inte-
grated Data Analysis System) Quantum 
pharmaceutical market research service 
(IMS Health, Philadelphia, USA). Data 
were expressed in standard units for the 
volume of sales and in constant United 
States dollars (US$) for the value of 
sales. A standard unit, as defined by IMS 
Health, is the smallest dose of a product 
– it may be one tablet or capsule for oral 
preparations, one teaspoon (i.e. 5 mL) 
for a syrup or one ampoule or vial for 
an injectable product. The value of sales 
was derived from the price deemed most 
accurate for the relevant country and 
was expressed in constant US$, which 
were calculated by converting the local 
currency into United States dollars at a 
constant exchange rate. In most coun-
tries, the price used was the ex-factory 
price; in Estonia, Finland, Greece and 
Ireland, ex-factory prices were derived 
from wholesale prices. Average stan-
dard conversion factors, which were 
determined with the co-operation of 
the pharmaceutical industry for each 
country, were applied to estimate prices 
at various points along the distribution 
chain. The price calculations did not 
take into account any discounts between 
manufacturers, wholesalers and payers 
and were not adjusted for inflation.
Our study considered only prescrip-
tion medicines, whether on or off patent, 
that were available in the retail market 
for the 10 highest-selling therapeutic 
classes. We identified the 10 highest-
selling classes by ranking therapeutic 
classes according to their sales volume 
in each country. Together the combined 
sales volume of products in these 10 
classes accounted for at least 50% of 
the total sales volume of all medicines 
in each of the eight countries from 2008 
to 2011 (Table 2). Data were aggregated 
by therapeutic class for each country. We 
had no data on individual drugs.
Country groups
We considered eight European countries 
in which the majority of the population 
was covered by a social security system 
or national health service: Austria, Esto-
nia, Finland, Greece, Ireland, Portugal, 
Slovakia and Spain. We selected these 
countries because they represented a va-
riety of geographical regions and levels 
of economic wealth and stability and had 
been affected by the recession to differ-
ent degrees. We classified them as either 
economically less stable or economi-
cally stable using categories defined 
by the Organisation for Economic Co-
operation and Development (OECD) 
for the level of fiscal consolidation in 
2012. Fiscal consolidation was judged 
according to whether the country had 
adopted either concrete policies aimed 
at stabilizing general government gross 
debt or a long-term target for the debt-
to-GDP ratio of 60%. There were four 
categories of country: (i) those that had 
adopted a programme proposed by the 
International Monetary Fund, the Euro-
pean Union and the European Commis-
sion (e.g. Greece, Ireland and Portugal); 
(ii) those that were under clear market 
pressure (e.g. Belgium, Hungary, Italy, 
Slovakia and Spain); (iii) those that had 
a substantial deficit or debt but which 
were under less market pressure (e.g. 
Austria, Denmark, Finland, France and 
Germany); and (iv) those that had no 
or only a marginal need for consolida-
tion (e.g. Norway, Sweden and Switzer-
land).21 In this study, we regarded eco-
nomically less stable countries as those 
belonging to the first two categories (i.e. 
Greece, Ireland, Portugal, Slovakia and 
Spain) and economically stable coun-
tries as those belonging to the third and 
fourth categories (i.e. Austria, Estonia 
and Finland).
Data analysis
First, we described and analysed the 
number of policy measures implement-
ed per year, per country group and per 
policy category. Next, we determined the 
volume and value of the sales of drugs in 
each therapeutic class between 2006 and 
2011 in each country and, then, we cal-
culated the combined volume and value 
of the sales of drugs for all 10 therapeutic 
classes for each country. Since our find-
ings for individual therapeutic classes 
and for all therapeutic classes combined 
were similar, we present only the results 
for all therapeutic classes combined.
For this analysis, we divided the 
volume and value of sales by the size of 
the country’s population to control for 
population growth; annual population 
figures were obtained from the OECD.22
We derived the annual and average 
growth rates over the study period using 
both the volume and value of pharma-




























where AGR is the annual growth rate, 
Sy is the per capital sales in a year, Sy–1 is 
the per capital sales in the previous year, 
AAGR is the average annual growth rate 
and n is the number of years.
To compare changes in the volume 
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Table 1.  National policy measures influencing pharmaceutical sales19
Policy measure Definition
Pricing
Price cut A cost-containment measure whereby the set price of a medicine is reduced by the authorities.
External price referencing External price referencing is the practice whereby the price of a medicine in one or several other 
countries is used to derive a benchmark or reference price for the purpose of setting or negotiating the 
medicine’s price in a given country.
Policy changes in external price referencing include the introduction or abolition of this pricing 
policy and altering the methodology (e.g. changing the basket of reference countries or the way of 
calculating the benchmark price).
Distribution remuneration  
(i.e. mark-ups, margins and fees  
for service)
Distribution remuneration is the payment of a health-care provider, whether an individual or an 
organization, for the services provided. In the distribution of pharmaceuticals, wholesalers and 
pharmacies are remunerated using mark-ups or regressive margin schemes or, for pharmacies alone, by 
paying a “fee for service”. With mark-ups, a defined linear or percentage amount is added to the cost of 
a good to ensure a profit at the wholesale or retail level or both. With regressive margin schemes, the 
margin is expressed as a percentage of the selling price.
Policy changes in distribution remuneration include adjusting the mark-ups or margins used for 
wholesalers or pharmacies or changing the type of distribution remuneration for a defined actor. 
Changes may also be made to the types of medicines (e.g. reimbursable medicines or prescription-only 
medicines) to which distribution remuneration applies.
VAT on medicine VAT is a sales tax on products that is collected in stages. It is a wide-ranging tax that is usually designed 
to cover most or all goods and services, including medicines.
Policy changes in VAT include the introduction or abolition of VAT on medicines and altering the VAT 
rate on medicines.
Extraordinary price review Price reviews involve reviewing the process by which the set price of a medicine was established. 
Reviews may or may not be performed in combination with reimbursement reviews. Reviews can be 
performed systematically (e.g. once a year) for all reimbursed medicines or for a group of medicines 
(e.g. for a specific indication) or at any time.
Reimbursement
Reference price system With a reference price system, which is also referred to as internal or therapeutic reference pricing, the 
third party payer determines a reference price for the reimbursement of medicines with a particular 
active ingredient or in a given therapeutic class. If the price of the medicine exceeds the reference 
price, the health-care consumer must pay the difference between the fixed reimbursed amount 
(i.e. the reference price) and the actual pharmacy retail price in addition to any copayments (e.g. 
prescription costs and percentage copayment rates).
Policy changes in the reference price system include the introduction or abolition of a reference price 
system and changing the methodology by which clusters of medicines are established for determining 
a reference price (e.g. by grouping identical or similar medicines).
Out-of-pocket payments Out-of-pocket payments are payments made by health-care consumers that are not reimbursed by a 
third-party payer. They include cost-sharing, fixed or percentage copayments and informal payments 
to health-care providers.
Delisting Delisting is the exclusion of a medicine from a reimbursement list (e.g. a positive list), which often 
results in exclusion from reimbursement.
Generic drugs
INN prescribing With INN prescribing, prescribers (e.g. physicians) are required to prescribe medicines using the INN for 
the pharmaceutical (i.e. the name of the active ingredient) instead of a brand name.
Policy changes in INN prescribing include its introduction or abolition, changing the way INN 
prescribing is organized (e.g. by imposing or eliminating financial incentives) and changing from 
indicative to obligatory INN prescribing.
Generic substitution Generic substitution is the practice of substituting a medicine, whether marketed under a trade name 
or generic name (i.e. a branded or unbranded drug), by a less expensive medicine (e.g. a branded or 
unbranded generic drug), which often contains the same active ingredients. Generic substitution may 
be encouraged (i.e. indicative generic substitution) or required (i.e. mandatory generic substitution).
Policy changes in generic substitution include its introduction or abolition, changing the way generic 
substitution is organized (i.e. imposing or eliminating financial incentives) and moving from indicative 
to obligatory generic substitution.
Public campaigns Policies, regulations, measures and initiatives promoting the use of generic drugs or licensed, off-
patent medicines are typically undertaken by government authorities. Policy on generic drugs may be 
targeted at prescribers, pharmacists, patients or consumers, or other stakeholders.
INN: international nonproprietary name; VAT: value-added tax.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 633
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ference between the annual growth rate 
in the value of pharmaceutical sales and 
the annual growth rate in the volume of 
sales for each country.
Results
Changes in policy
Table 3, Table 4 and Table 5 (avail-
able at: http://www.who.int/bulletin/
volumes/92/9/13-129114) summarize 
the 88 policy changes we identified in 
pricing, reimbursement and generic 
drugs, respectively. Economically stable 
countries implemented 7 or fewer policy 
changes each between 2008 and 2011; 
the lowest number was 2 in Finland 
(Table 6). Less economically stable 
countries implemented between 10 and 
22 changes each; the highest number was 
22 in Portugal. The greatest number of 
policy adjustments occurred in 2010 
(33) and 2011 (40) and the most fre-
quently used policy measures involved 
changes in out-of-pocket payments 
by patients (16), changes in regula-
tions controlling the mark-up of prices 
(13) and price reductions (11). Some 
countries implemented several pricing 
measures. For example, Spain enacted 
four price cuts between 2008 and 2011. 
Most changes concerned reimbursable 
medicines and built on existing poli-
cies; only a few changes involved newly 
implemented policies, such as the in-
troduction of internal reference pricing 
in Finland.17
Changes in sales
The small increase in the volume of 
pharmaceutical sales in all countries 
between 2006 and 2011 is shown in 
Fig. 1, Fig. 2, Fig. 3, Fig. 4 and Table 7: 
the average annual per capita growth 
in sales volume ranged from 0.8% in 
Greece and 1.0% in Portugal to 3.7% in 
Ireland, 4.0% in Slovakia and 4.6% in 
Estonia. However, annual growth rates 
were much more variable: from 2006 to 
2007 the growth rate was over 3.7% for 
all countries, with Estonia having the 
highest rate at 12.2%. Between 2007 
and 2009, growth remained fairly stable 
in Austria and Finland but there was 
a sharp decline in Estonia: the annual 
growth rate was −0.5% from 2007 to 
Table 2.  Ten highest-sellinga therapeutic drug classes in eight European countries,b 
2008–2011
Third-level code of the ATC classification20 Therapeutic class




B01C Platelet aggregation inhibitors
C10A, C10C and C11A Lipid regulators
C09A and C09B ACE inhibitors, either as single agents or in 
combination with other antihypertensives
M01A and M02A Antirheumatics
N02A Non-narcotic analgesics
N06A Antidepressants
R01A6, R01B and R06A Antiallergy drugs: systemic and nasal 
preparations and topical products
R03A, R03B, R03C, R03D, R03E, R03F, R03G, 
R03H, R03I, R03J and R03X
Respiratory agents
ACE: angiotensin-converting enzyme; ATC: Anatomical Therapeutic Chemical.
a  Together the products in these classes accounted for at least 50% of sales by volume in each country 
under investigation.
b  Austria, Estonia, Finland, Greece, Ireland, Portugal, Slovakia and Spain.
Table 6.  Policy measures influencing pharmaceutical sales in eight European countries, 2008–2011
Policy measure No. of measures implemented between 2008 and 2011a Total
Economically stable countriesb Economically less stable countriesb
Austria Estonia Finland Greece Ireland Portugal Slovakia Spain
Pricing
Price cuts 0 0 0 2 2 3 0 4 11
External price referencing 0 0 0 3 0 2 2 1 8
Distribution remuneration 0 1 0 3 3 3 0 3 13
VAT on medicines 1 1 0 1 1 1 0 1 6
Extraordinary price review 0 0 0 2 2 1 1 1 7
Reimbursement
Internal reference pricing 0 1 1 1 0 2 2 1 8
Out-of-pocket payments 4 1 0 0 1 5 3 2 16
Delisting 0 0 1 2 0 1 0 1 5
Generics
INN prescribing 0 1 0 0 0 1 1 1 4
Generic substitution 0 0 0 0 0 0 0 0 0
Public campaigns and other 
generic policies
1 2 0 0 1 3 1 2 10
Total 6 7 2 14 10 22 10 17 88
INN: international nonproprietary name; VAT: value-added tax.
a  The number of measures implemented in each year was: 4 in 2008; 11 in 2009; 33 in 2010; and 40 in 2011.
b  The three economically stable countries implemented 15 measures during 2008–2011 compared with 73 in the five economically less stable countries.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 634
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2008 and −9.0% from 2008 to 2009. The 
growth rate declined in all economically 
less stable countries but more gradually. 
After the steep year-on-year decline in 
Estonia in 2009, the volume of sales grew 
17.1% from 2009 to 2010. In contrast, 
the volume continued to decline in 
economically less stable countries: for 
example, from 2009 to 2010, there was 
a decline of −4.1% in Greece and −0.5% 
in Portugal. From 2010 to 2011, two of 
the less economically stable countries 
experienced a high growth in sales vol-
ume (5.5% in Spain and 7.8% in Ireland), 
while the growth rate was between 1.0% 
and 3.1% in most other less economi-
cally stable countries. The exception was 
Portugal, which experienced a decline 
of −3.7%.
The average annual per capita 
growth in the value of sales between 
2006 and 2011 varied between −2.1% 
in Portugal and 6.0% in Estonia. Af-
ter 2009, all countries except Austria 
experienced a decrease in the value 
of sales in at least one year. The larg-
est annual declines were observed in 
Greece (−13.5% from 2009 to 2010) and 
Portugal (−11.1% from 2010 to 2011). 
Moreover, the value of sales declined 
from 2010 to 2011 in all economically 
less stable countries. 
Fig. 5 depicts the difference be-
tween the annual growth rate in the 
value of pharmaceutical sales and the 
annual growth rate in the volume of sales 
in each country between 2006 and 2011. 
In general, between 2006 and 2008, the 
annual value of pharmaceutical sales 
increased more than the annual volume 
of sales in both economically stable and 
less stable countries, which indicates 
that the average price per unit increased. 
From 2009 onwards, during the period 
when most policy changes were imple-
mented, the growth in the annual value 
of sales was less than the growth in the 
annual volume, which indicates a de-
crease in average price per unit.
Discussion
Although countries adjust their phar-
maceutical policy frameworks continu-
ously, a surge of policy changes seems to 
have taken place during the economic 
recession, particularly in 2010 and 2011. 
Unexpectedly, both economically stable 
and economically less stable countries 
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a   The volume of pharmaceutical sales is for the 10 highest-selling therapeutic classes in each country.
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a   The volume of pharmaceutical sales is for the 10 highest-selling therapeutic classes in each country.
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a   The value of pharmaceutical sales is for the 10 highest-selling therapeutic classes in each country.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 635
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experienced a slight increase in the 
consumption of pharmaceuticals in the 
10 highest-selling therapeutic classes, 
as measured in standard units per 
capita. As expected, the annual growth 
in the per capita value of medicine sales 
decreased in economically less stable 
countries in 2010 and 2011.
Our study shows that economi-
cally stable countries implemented fewer 
policy measures between 2008 and 2011 
than economically less stable countries. 
The most frequently implemented 
policy changes targeted out-of-pocket 
payments for patients. Previous studies 
have shown that increases in copay-
ments, such as prescription fees, tend 
to lead to lower medicine utilization, 
especially in times of economic reces-
sion and increased unemployment.23–30 
Policy measures such as the medicine 
price cuts (also applied in the form of 
discounts) that were implemented in 
Greece, Portugal and Spain could have 
had a negative effect on the availability of 
medicines if they caused pharmaceutical 
companies to withdraw their products 
from national reimbursement lists.31 
Contrary to our expectations, however, 
we did not observe a major decline in 
the consumption of pharmaceuticals 
during the recession in the therapeutic 
categories studied as most countries 
continued to experience a moderate 
positive annual growth in sales volume. 
However, in line with media reports of 
drug shortages in Greece and Portugal, 
our data showed that the sales volumes 
of important medicines for chronic 
diseases, such as angiotensin-converting 
enzyme inhibitors and antidepressants, 
dropped drastically in these two coun-
tries in 2010.31 Hence, although the over-
all growth in sales volume was positive, 
the rate of growth appears to have fallen 
to below the prerecession level, which 
ranged from 5% to 12%.
In contrast, the rate of growth in 
the value of pharmaceutical sales de-
clined, especially in economically less 
stable countries. This decrease may have 
been due partly to inflation: the average 
inflation rate in 2010 and 2011 gener-
ally ranged between 2.0% and 3.4%, 
although it was as low as −1.6% in 2010 
in Greece and as high as 5.1% in 2011 
in Estonia.32 Our analysis did not take 
inflation into account. The decrease 
may also have occurred because the 























































2006 2007 2008 2009 2010 2011
Greece Slovakia Portugal Ireland Spain
US$: United States dollars.
a   The value of pharmaceutical sales is for the 10 highest-selling therapeutic classes in each country.
Table 7.  Per capita growth in pharmaceutical sales for the 10 highest-selling 
therapeutic classes in eight European countries, by volume and value, 
2006–2011
















  Austria 4.6 4.0 2.7 1.5 1.1 2.8
  Estonia 12.2 −0.5 −9.0 17.1 3.1 4.6
  Finland 3.7 3.8 2.3 3.4 1.0 2.8
Economically less 
stable countries
  Greece 5.6 0.3 0.7 −4.1 1.5 0.8
  Ireland 4.1 1.4 4.3 0.8 7.8 3.7
  Portugal 6.1 1.8 1.1 −0.5 −3.7 1.0
  Slovakia 6.1 7.1 1.7 4.1 1.0 4.0




  Austria 7.3 6.3 2.2 0.4 1.5 3.5
  Estonia 20.5 5.2 0.3 7.0 −3.2 6.0
  Finland 3.1 6.3 −2.2 −2.6 0.7 1.1
Economically less 
stable countries
  Greece 13.3 7.0 6.8 −13.5 −2.4 2.2
  Ireland 7.6 7.2 3.6 −1.9 −3.4 2.6
  Portugal 5.4 2.0 −2.2 −4.6 −11.1 −2.1
  Slovakia 12.0 14.6 0.6 0.5 −0.9 5.4
  Spain 6.1 3.1 2.7 −0.4 −3.7 1.6
a  The volume of sales was measured in standard units per capita (IMS Health, unpublished data, 2012).
b  The value of sales was measured in constant United States dollars per capita (IMS Health, unpublished 
data, 2012).Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 636
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pharmaceutical policies implemented 
in economically less stable countries 
had the desired effect of lowering public 
spending while maintaining access to 
medicines at a relatively stable level. For 
example, utilization could have shifted 
to less expensive or generic medicines. 
Nevertheless, even if sales volumes were 
maintained at lower prices, since several 
policy measures probably increased out-
of-pocket payments for patients, the 
financial burden on patients may have 
increased.
The case of Estonia needs to be 
discussed separately. After a decade of 
rapid growth before the recession, during 
which public sector expenditure grew 
6.5 times,21 Estonia experienced a major 
decline in GDP in 2009. Public sector 
spending was cut by 6.6% – a reduction 
of 100 million euros compared with 2008 
– and there was a 50 million euros reduc-
tion in health insurance expenditure.33 A 
previous study identified a large decline 
in the consumption of pharmaceuticals 
of −18% between 2008 and 2009,16 which 
was mirrored in our data. In response, 
Estonia implemented strict cost-saving 
measures with respect to medicines, re-
duced sick leave coverage and increased 
the workload of clinical staff without 
increasing their salaries.16,33 Our data 
show that, by 2010, the consumption 
of pharmaceuticals had returned to a 
level similar to that before the recession, 
which paralleled Estonia’s relatively quick 
recovery from the recession overall.21
Early in the recession, countries not 
only implemented few policies changes 
overall but also implemented no policies 
that targeted consumption by specific 
patient groups or in specific therapeutic 
areas. Recent studies show that fewer 
policy changes were implemented in 
2012 and 2013 than during the recession 
and that there was a trend towards poli-
cies that targeted high-cost medicines.34 
Several countries have explored alterna-
tive policies for sharing the financial risk 
of selected, new, high-cost medicines, 
such as value-based pricing models or 
risk-sharing agreements.35–38 The effect 
of these new approaches still needs to 
be determined.
Our study had several limitations. 
We did not take into account the dif-
ferences in pharmaceutical policy 
frameworks that existed between all 
countries before the economic recession 
or between regions within some coun-
tries (e.g. Italy or Spain). Moreover, it 
was not always clear whether a country 
implemented a policy as a short-term 
reaction to recession-related budgetary 
constraints or whether the policy was 
part of a planned long-term change to 
the system. For instance, in Finland, 
the implementation of internal refer-
ence pricing in 2009 had been planned 
long before the recession.39 Major policy 
changes, such as the introduction of 
reference price systems, may take several 
years to implement since many stake-
holders are involved.40 However, most of 
the policy changes related to the reces-
sion involved adjusting existing policies 
and could be implemented relatively 
quickly. Although these policies might, 
as desired, contain costs over the short-
term, they could have substantial long-
term effects on the use and affordability 
of medicines and could have negative 
consequences for health.41–44 We focused 
our analysis on the sale of products that 
accounted for the majority of pharma-
ceutical sales by volume. It is possible 
that policy changes had a differential 
influence on the sale of less frequently 
used products, including those used by 
patients with rare diseases. However, at 
least one price cut in Greece exempted 
orphan drugs for rare diseases.
Another limitation is that, since 
data on the value of sales are expressed 
in constant US$ and disregard discounts 
and rebates, they do not reflect actual 
spending by third-party payers. In addi-
tion, an individual country’s data might 
include different products within each 
therapeutic class. Moreover, medicines 
sales may also be influenced by other 
market variables, such as patent expira-
tion. During the study period, patents 
expired on several highly used products, 
including diabetes medications, antiul-
cerants, platelet aggregation inhibitors, 
lipid regulators, angiotensin-converting 
enzyme inhibitors and antidepressants. 
The price reductions accompanying 
patent expiries may have combined with 
policies promoting generic prescribing 
to reduce the value of sales while limit-
ing the decline in sales volume. Finally, 
the rapid implementation and the dif-
ferent timing of policies in different 
countries meant that we were unable to 
attribute the observed change in phar-
maceutical sales to any single policy 
or set of policies or to make statistical 
comparisons of responses to policy be-
tween countries.
We suggest that future research 
focuses on the effect of policy changes 
in only a few countries by exploring the 
relationship between changes in medi-
cine utilization and health outcomes. 
Moreover, since some of our findings 
were not in line with our expectations, 
we recommend that studies of the effect 
Fig. 5.  Difference between the annual growth in the value and volume of 



















































































         2006–2007 2007–2008 2008–2009 2009–2010 2010–2011
Austria
Spain Portugal Slovakia Ireland
Estonia Economically stable
Economically  less stable Greece
Finland
a   The graph illustrates the percentage point difference between the annual percentage growth in the 
value of pharmaceutical sales for the 10 highest-selling therapeutic classes and the annual percentage 
growth in the volume of sales. The volume of sales was measured in standard units per capita and the 
value of sales was measured in constant United States dollars (US$) per capita.
b  A negative value implies that the volume of sales increased more in a year than the value of sales, 
which indicates a decrease in the average price per unit.
c   Austria, Estonia, Finland, Greece, Ireland, Portugal, Slovakia and Spain.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 637
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of new pharmaceutical policies should 
monitor access to medicines and look 
for potential barriers to access.
In conclusion, the ways in which 
countries responded to the recession 
differed greatly, with less economically 
stable countries implementing a larger 
number of policies that affected the 
pharmaceutical sector than economi-
cally stable countries. Our evidence 
shows that, despite numerous policy 
changes and contrary to our expecta-
tions, overall consumption of phar-
maceuticals in the 10 highest-selling 
therapeutic classes continued to increase 
in most countries; there was no clear 
difference between economically stable 
and less stable countries. The observa-
tion that the value of sales declined 
while the volume was maintained may 
indicate that pharmaceutical purchasing 
became more efficient. However, since 
many policies were designed to shift 
the financial burden to patients, future 
research should investigate the effect 
of changes in pharmaceutical policy, 
expenditure and utilization on equitable 
access to medicines, on the affordability 
of essential medicines for households, 
on the appropriate use of medicines and 
on health outcomes. ■
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صخلم
ةيبوروأ نادلب ةينماث في ةيودلأا تاعيبمو ةينلاديصلا تاضرحتسلما ةسايس لىع يداصتقلاا داسكلا يرثأت
 ءانثأ ةينلاديصلا تاضرحتسلما ةسايس في تايرغتلا ديدتح ضرغلا
 تناك اذإ ام ديدتحو ،ةيبوروأ نادلب ةينماث في يداصتقلاا داسكلا
 تاضرحتسلما  تاعيبم  ضافخنا  لىإ  تدأ  دق  ةسايسلا  يربادت
.اهيلع قافنلإا ضافخناو ةينلاديصلا
 ةسايس  في  تايرغتلا  نع  تامولعم  لىع  لوصلحا  مت  ةقيرطلا
 ةينماث  في  2011و  2008  يماع  ينب  ةينلاديصلا  تاضرحتسلما
 تاضرحتسلما ةسايس تانايب دعاوقو تاروشنلما نم ةيبوروأ نادلب
 تاعيبلما ةميقو مجح نأشب تانايب لىع لوصلحا متو .ةينلاديصلا
 تائفلا في 2011و 2006 يماع ينب تاجتنملل  ةيونسلا عبر
 ثاحبلأ تانايب ةدعاق نم دلب لك في ًاعيبم لىعلأا شرعلا ةيجلاعلا
 في تاشرؤلما هذه ةنراقمب انمقو .ةينلاديصلا تاضرحتسلما قوس
 تاشرؤلماب ادنلنفو اينوتسإو اسمنلا يهو ًايداصتقا ةرقتسلما نادلبلا
 لاغتبرلاو  ادنلريأو  نانويلا  يهو  ًارارقتسا  لقلأا  نادلبلا  في
.اينابسإو ايكافولسو
 تايرغت ةعبس لىإ يننثا نم ًايداصتقا ةرقتسلما نادلبلا تذفن جئاتنلا
 10 نم ًارارقتسا لقلأا نادلبلا تذفن مانيب ،اهنم لك تاسايس في
 تاسايسلا في ًايرغت 33 ثدحو .اهنم لك تاسايس في ًايرغت 22 لىإ
 لصأ نم 2011 ماع في تاسايسلا في ًايرغت 40و 2010 ماع في
 يريغت  كلذ  لمشو  .اهديدتح  مت  يتلا  تاسايسلا  في  ًايرغت  88
 ةلاح 16 في ةصالخا مبهويج نم ضىرلما اهلمحتي يتلا تاعوفدلما
 11 في راعسلأا ضفخو ةلاح 13 في راعسلأا حبر شماه مظنو
 نادلبلا عيجم في طسوتم وحن لىع تاعيبلما ماجحأ تدادزاو .ةلاح
 ماع دعب ةفيفط تاضافخنا ادهش نيذللا لاغتبرلاو نانويلا ءانثتساب
 انهأ يرغ ،نادلبلا يتعوممج في تاعيبلما ماجحأ تضفخناو .2009
.ًارارقتسا لقلأا نادلبلا في بركأ وحن لىع تضفخنا
 ةيداصتقلاا ةيحانلا نم ًارارقتسا لقلأا نادلبلا تذفن جاتنتسلاا
 ءانثأ ةينلاديصلا تاضرحتسلما ةسايس لىع تايرغتلا نم ديزلما
 تاعيبم ماجحأ تدادزاو .ًايداصتقا ةرقتسلما نادلبلا نع داسكلا
 نادلبلا عيجم في ،عقوتم يرغ وحن لىع ،ةينلاديصلا تاضرحتسلما
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Résumé
Effet de la récession économique sur la politique pharmaceutique et les ventes de médicaments dans huit pays européens
Objectif Identifier les changements de politique pharmaceutique 
au cours de la récession économique dans huit pays européens et 
déterminer si les mesures politiques ont entraîné une baisse des ventes 
et des dépenses en matière de produits pharmaceutiques.
Méthodes Les informations relatives aux changements de la politique 
pharmaceutique entre 2008 et 2011 dans huit pays européens ont 
été obtenues à partir des publications et des bases de données sur 
la politique pharmaceutique. Les données sur le volume et la valeur 
des ventes trimestrielles des produits entre 2006 et 2011 pour les 
10 classes thérapeutiques les plus vendues dans chaque pays ont été 
obtenues à partir d’une base de données d’études de marché sur les 
médicaments. Nous avons comparé ces indicateurs dans des pays 
économiquement stables: Autriche, Estonie et Finlande, par rapport 
aux indicateurs mesurés dans des pays moins stables: Grèce, Irlande, 
Portugal, Slovaquie et Espagne.
Résultats Les pays économiquement stables ont chacun mis en œuvre 
2 à 7 changements de politique, tandis que les pays moins stables en 
ont mis en œuvre 10 à 22 chacun. Sur les 88 changements de politique 
identifiés, 33 ont eu lieu en 2010 et 40 en 2011. Ils impliquaient des 
changements dans les paiements restants à charge pour les patients 
dans 16 cas, des plans d’augmentation des prix dans 13 cas et des 
baisses de prix dans 11 cas. Les volumes des ventes ont augmenté 
modérément dans tous les pays à l’exception de la Grèce et du Portugal 
qui ont connu de légères baisses après 2009. Les valeurs des ventes ont 
diminué dans les deux groupes de pays, mais elles ont davantage chuté 
dans les pays moins stables.
Conclusion Les pays moins stables économiquement ont mis en œuvre 
plus de changements de politique pharmaceutique au cours de la 
récession que les pays économiquement stables. De manière inattendue, 
les volumes des ventes de médicaments ont augmenté dans presque 
tous les pays, alors que les valeurs des ventes ont baissé, en particulier 
dans les pays moins stables.
Резюме
Влияние экономического спада на фармацевтическую политику и продажи медикаментов в восьми 
европейских странах
Цель Идентифицировать изменения фармацевтической политики 
в период экономического спада в восьми европейских странах и 
определить, привели ли политические меры к снижению продаж 
фармацевтических препаратов и расходов на них.
Методы Информация об изменениях в фармацевтической 
политике за период 2008-2011 гг. в восьми европейских странах 
была получена из публикаций и баз данных фармацевтической 
политики. Данные об объемах и суммах квартальных продаж 
продукции за 2006-2011 гг. для десяти самых продаваемых 
терапевтических классов в каждой стране были получены из 
базы данных исследований фармацевтического рынка. Были 
сопоставлены показатели экономически стабильных стран 
(Австрия, Эстония и Финляндия) с подобными показателями 
менее стабильных стран (Греция, Ирландия, Португалия, Словакия 
и Испания).
Результаты В каждой из экономически стабильных стран было 
реализовано от 2 до 7 изменений в политике, в то время как в 
каждой из менее стабильных странах – от 10 до 22 изменений. 
Из 88 выявленных изменений в фармацевтической политике 
33 произошли в 2010 году и 40 – в 2011 году. Они включали: 
изменения неофициальных расходов для пациентов в 16 
случаях, схемы повышения цен в 13 случаях и снижение цен в 
11 случаях. Объемы продаж умеренно выросли во всех странах, за 
исключением Греции и Португалии, где имелось незначительное 
снижение после 2009 года. Продажная стоимость снизилась в 
обеих группах стран, причем в более значительной степени в 
менее стабильных странах.
Вывод Экономически менее стабильные страны реализовали 
больше изменений фармацевтической политики в период 
экономического спада, чем экономически стабильные страны. 
Неожиданным результатом явилось то, что объемы продаж 
фармацевтической продукции увеличились практически во всех 
странах, тогда как продажная стоимость снизилась, особенно в 
менее стабильных странах.
Resumen
El efecto de la recesión económica sobre la política farmacéutica y la venta de medicinas en ocho países europeos
Objetivo Identificar los cambios en las políticas farmacéuticas en ocho 
países europeos durante la recesión económica y determinar si las 
medidas de política dieron lugar a una reducción en las ventas y a un 
gasto menor en productos farmacéuticos.
Métodos La información sobre los cambios en las políticas farmacéuticas 
entre 2008 y 2011 en ocho países europeos se obtuvo a partir de 
publicaciones y bases de datos sobre políticas farmacéuticas. Los 
datos sobre el volumen y valor de las ventas trimestrales de productos 
entre 2006 y 2011 en las 10 clases terapéuticas más vendidas en 
cada país se obtuvieron de una base de datos de investigación del 
mercado farmacéutico. Comparamos estos indicadores en los países 
económicamente estables (Austria, Estonia y Finlandia) con los de los 
países menos estables (Grecia, Irlanda, Portugal, Eslovaquia y España).
Resultados Cada uno de los países económicamente estables 
implementó entre dos y siete cambios de políticas, mientras que los 
países menos estables implementaron entre 10 y 22 cada uno. De los 
88 cambios de políticas identificados, 33 tuvieron lugar en el año 2010 
y 40, en el año 2011. Implicaron cambios en los pagos directos por 
atención sanitaria para pacientes en 16 casos, programas de aumento 
de precios en 13 casos y recortes de precios en 11. Los volúmenes de 
ventas aumentaron moderadamente en todos los países excepto en 
Grecia y Portugal, que experimentaron descensos ligeros a partir de 
2009. El valor de las ventas disminuyó en ambos grupos de países, si 
bien fue mayor en los países menos estables.
Conclusión Los países económicamente menos estables implementaron 
más cambios en las políticas farmacéuticas durante la recesión que los 
países económicamente estables. Sorprendentemente, los volúmenes 
de ventas de productos farmacéuticos aumentaron en casi todos los 
países, mientras que el valor de las ventas disminuyó, especialmente 
en los países menos estables.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 639
Research
Economic recession and pharmaceutical policies
References
1.  Habl C, Antony K, Entleitner M, Fröschl B, Leopold C, Stürzlinger H, et al. 
Surveying, assessing and analyzing the pharmaceutical sector in the 25 EU 
Member States. Luxembourg: European Communities; 2006. Available from: 
http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf [cited 
2014 May 7].
2.  Mossialos E, Mrazek M, Walley T. Regulating pharmaceuticals in Europe: 
striving for efficiency, equity, and quality. European Observatory on Health 
Care Systems series. Maidenhead: Open University Press; 2004.
3.  Docteur E, Paris V. Pharmaceutical pricing policies in a global market. Paris: 
The Organisation for Economic Co-operation and Development; 2008.
4.  Seiter A. Access to medicines and the innovation dilemma – Can 
pharmaceutical multinationals be good corporate citizens? Bus Ethics 
Innov Ethics Sci Technol Assess. 2007;31:89–100. doi: http://dx.doi.
org/10.1007/978-3-540-72310-3_6
5.  Shelburne R, Trentini C. Public health in Europe: the 2007–2009 financial 
crisis and UNECE activities. Discussion paper series No. 2009.2. Geneva: 
United Nations Economic Commission for Europe; 2009. Available from: 
http://www.unece.org/fileadmin/DAM/oes/disc_papers/ECE_DP_2009-2.
pdf [cited 2013 Feb 10].
6.  The economic situation in 2008-2009 in the Economic Commission 
for Europe region: Europe, North America and the Commonwealth of 
Independent States. Geneva: United Nations Economic and Social Council; 
2009. Available from: http://daccess-dds-ny.un.org/doc/UNDOC/GEN/
N09/331/44/PDF/N0933144.pdf?OpenElement [cited 2014 May 07].
7.  Schrader K, Laaser CF. Die Krise in Südeuropa oder die Angst vor dem 
Dominoeffekt. Griechenland, Portugal und Spanien im Krisentest. Kiel: 
Institut für Weltwirtschaft; 2012. German. Available from: http://www.
ifw-kiel.de/pub/kd/2012/kd500-501.pdf [cited 2014 May 7].
8.  Averting a human crisis during the global downturn: policy options from 
the World Bank’s Human Development Network. Washington: World Bank; 
2009. Available from: http://siteresources.worldbank.org/NEWS/Resources/
AvertingTheHumanCrisis.pdf [cited 2014 May 7].
9.  Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M. The public health effect 
of economic crises and alternative policy responses in Europe: an empirical 
analysis. Lancet. 2009;374(9686):315–23. doi: http://dx.doi.org/10.1016/
S0140-6736(09)61124-7 PMID: 19589588
10.  Holahan J. The 2007–09 recession and health insurance coverage. Health 
Aff (Millwood). 2011;30(1):145–52. doi: http://dx.doi.org/10.1377/
hlthaff.2010.1003 PMID: 21134911
11.  Lusardi A, Schneider D, Tufano P. The economic crisis and medical care 
usage. National Bureau of Economic Research Working Paper. Hanover: 
Dartmouth College; 2010. Available from: http://www.dartmouth.
edu/~alusardi/Papers/healthcare_031610.pdf [cited 2014 May 7].
12.  Fronstin P. The impact of the recession on employment-based health 
coverage. EBRI Issue Brief. 2010;342(342):1–22. PMID: 20578430
13.  Truffer CJ, Keehan S, Smith S, Cylus J, Sisko A, Poisal JA, et al. Health 
spending projections through 2019: the recession’s impact continues. 
Health Aff (Millwood). 2010;29(3):522–9. doi: http://dx.doi.org/10.1377/
hlthaff.2009.1074 PMID: 20133357
14.  McKee M, Stuckler D, Martin-Moreno JM. Protecting health in hard times. 
BMJ. 2010;341:c5308. doi: http://dx.doi.org/10.1136/bmj.c5308 PMID: 
20880907
15.  Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler 
D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 
2011;378(9801):1457–8. doi: http://dx.doi.org/10.1016/S0140-
6736(11)61556-0 PMID: 21988763
16.  Buysse IM, Laing RO, Mantel-Teeuwisse AK. Impact of the economic 
recession on the pharmaceutical sector [Internet]. Geneva: World Health 
Organization; 2010. Available from: http://apps.who.int/medicinedocs/
en/m/abstract/Js17419e/ [cited 2013 Feb 10].
17.  Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical 
policies in European countries in response to the global financial crisis. 
South Med Rev. 2011;4(2):69–79. doi: http://dx.doi.org/10.5655/smr.
v4i2.1004 PMID: 23093885
18.  de Belvis AG, Ferrè F, Specchia ML, Valerio L, Fattore G, Ricciardi W. The 
financial crisis in Italy: implications for the healthcare sector. Health Policy. 
2012;106(1):10–6. doi: http://dx.doi.org/10.1016/j.healthpol.2012.04.003 
PMID: 22551787
19.  Glossary of pharmaceutical terms. Update 2013. Vienna: World Health 
Organization Collaborating Centre for Pharmaceutical Pricing and 
Reimbursement Policies; 2013. Available from: http://whocc.goeg.at/
Literaturliste/Dokumente/MethodologyTemplate/PHIS%20Glossary_
Update2013_final_gesamt.pdf [cited 2014 Apr 30].
20.  Anatomical classification [Internet]. London: European Pharmaceutical 
Market Research Association; 2014. Available from: http://www.ephmra.
org/Anatomical-Classification [cited 2014 Apr 30].
21.  Restoring public finances, 2012 update [Internet]. Paris: Organisation for 
Economic Co-operation and Development; 2012. Available from: http://
www.oecd.org/gov/budgeting/restoringpublicfinances-reportoutliningthef
iscalconsolidationplansof30oecdcountries.htm [cited 2014 May 7].
22.  OECD. StatExtracts. Health. Demographic references [Internet]. Paris: 
Organisation for Economic Co-operation and Development; 2013. Available 
from: http://stats.oecd.org/ [cited 2014 May 7].
23.  Marmot MG, Bell R. How will the financial crisis affect health? BMJ. 
2009;338:b1314. doi: http://dx.doi.org/10.1136/bmj.b1314 PMID: 19359306
24.  Leyland AH. Alcohol, financial crisis and reform: learning from the 
Russian experience. Eur J Public Health. 2012;22(3):300. doi: http://dx.doi.
org/10.1093/eurpub/cks051 PMID: 22556037
25.  Polyzos N. Health and the financial crisis in Greece – author’s reply. Lancet. 
2012;379(9820):1002. doi: http://dx.doi.org/10.1016/S0140-6736(12)60421-
8 PMID: 22423876
26.  Yang BM, Prescott N, Bae EY. The impact of economic crisis on health-care 
consumption in Korea. Health Policy Plan. 2001;16(4):372–85. doi: http://
dx.doi.org/10.1093/heapol/16.4.372 PMID: 11739362
27.  Parry J, Humphreys G. Health amid a financial crisis: a complex diagnosis. 
Bull World Health Organ. 2009;87(1):4–5. doi: http://dx.doi.org/10.2471/
BLT.09.010109 PMID: 19197395
28.  Catalano R. Health, medical care, and economic crisis. N Engl J Med. 
2009;360(8):749–51. doi: http://dx.doi.org/10.1056/NEJMp0809122 PMID: 
19228617
29.  Navarro V. The crisis and fiscal policies in the peripheral countries of the 
Eurozone. Int J Health Serv. 2012;42(1):1–7. doi: http://dx.doi.org/10.2190/
HS.42.1.a PMID: 22403904
30.  Ornelas A. Recession-hit nations owe pharma firms billions [Internet]. Bern: 
Swissinfo.ch; 2012. Available from: http://www.swissinfo.ch/eng/business/
Recession-hit_nations_owe_pharma_firms_billions.html?cid=32185254 
[cited 2013 Jul 10].
31.  PGEU statement on medicine shortages in European Community 
pharmacies [Internet]. Brussels: Pharmaceutical Group of European 
Union; 2013. Available from: http://www.pgeu.eu/en/library/2-position-
papers/154-pgeu-statement-on-medicine-shortages-in-european-
community-pharmacies.html [cited 2013 Jun 10].
32.  Harmonised Indices of Consumer Prices (HICPs) – inflation rate. Annual 
average rate of change (%) 2006–2013 [Internet]. Brussels: EUROSTAT; 2013. 
Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&
plugin=1&language=en&pcode=tec00118 [cited 2014 Jan 20].
33.  Economic slowdown shaping healthcare system [Internet]. Gütersloh: 
Health Policy Monitor; 2009. Available from: http://hpm.org/en/Surveys/
PRAXIS_-_Estonia/13/Economic_slowdown_shaping_healthcare_system.
html [cited 2014 May 7].
34.  Leopold C, Vogler S, Bucsics A. Aktuelle Heilmittelausgaben und 
arzneimittelpolitische Trends in Europa. Soziale Sicherheit. 2013;9:414–29. 
German.
35.  Kanavos P, Nicod E, Espin J, van den Aardweg S. Short- and long-term 
effects of value-based pricing vs. external price referencing. Brussels: 
Directorate-General for Enterprise and Industry; 2010. Available from: 
http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/valuebased_
pharmapricing_012010_en.pdf [cited 2014 May 7].
36.  Husereau D, Cameron C. Value-based pricing of pharmaceuticals in Canada: 
opportunities to expand the role of health technology assessment? CHSRF 
series of reports on cost drivers and health systems efficiency: Paper 5 
[Internet]. Ottawa: Canadian Foundation for Healthcare Improvement; 
2011. Available from: http://www.cfhi-fcass.ca/SearchResultsNews/11-12-
16/8eeaf655-b2b6-4c39-a909-6854acfea850.aspx [cited 2014 May 7].Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 640
Research
Economic recession and pharmaceutical policies
37.  Espín J, Rovira J, García L. Experiences and impact of European risk-sharing 
schemes focusing on oncology medicines. Brussels: Directorate-General 
for Enterprise and Industry; 2011. Available from: http://ec.europa.eu/
enterprise/sectors/healthcare/files/docs/risksharing_oncology_012011_
en.pdf [cited 2014 May 7].
38.  Kanavos P. Ferrario A. Managed entry agreements for pharmaceuticals: 
the European experience. Brussels: Directorate-General for Enterprise and 
Industry; 2013. Available from: http://ec.europa.eu/enterprise/sectors/
healthcare/files/docs/mea_report_en.pdf [cited 2014 May 7]. 
39.  Pohjolainen L. Reference price and price competition – evidence from the 
Finnish pharmaceutical market [thesis]. Helsinki: Aalto University; 2012. 
Available from: https://aaltodoc.aalto.fi/handle/123456789/3456 [cited 
2012 Aug 20].
40.  Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B. Referenzpreissysteme in 
Europa. Analyse und Umsetzungsvoraussetzungen für Österreich. Vienna: 
ÖBIG Forschungs- und Planungsgesellschaft mbH; 2008. German.
41.  Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A. 
Influence of patient co-payments on atypical antipsychotic choice in 
Poland: implications once generic atypicals are available. Appl Health Econ 
Health Policy. 2011;9(2):101–10. doi: http://dx.doi.org/10.2165/11318840-
000000000-00000 PMID: 21271749
42.  Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A. Do policy 
changes in the pharmaceutical reimbursement schedule affect drug 
expenditures? Interrupted time series analysis of cost, volume and cost per 
volume trends in Sweden 1986–2002. Health Policy. 2006;79(2-3):231–43. 
doi: http://dx.doi.org/10.1016/j.healthpol.2006.01.007 PMID: 16473436
43.  Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law MR, et al. 
Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid 
following a policy change. Health Aff (Millwood). 2008;27(3):w185–95. doi: 
http://dx.doi.org/10.1377/hlthaff.27.3.w185 PMID: 18381404
44.  Ong M, Catalano R, Hartig T. A time-series analysis of the effect of increased 
copayments on the prescription of antidepressants, anxiolytics, and 
sedatives in Sweden from 1990 to 1999. Clin Ther. 2003;25(4):1262–75. doi: 
http://dx.doi.org/10.1016/S0149-2918(03)80082-6 PMID: 12809972Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 640A
Research


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































)Economic recession and pharmaceutical policies
Research
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































)Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 640C
Research





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.Bull World Health Organ 2014;92:630–640D| doi: http://dx.doi.org/10.2471/BLT.13.129114 640D
Research
Economic recession and pharmaceutical policies
T
a
b
l
e
 
5
.
 
P
o
l
i
c
y
 
c
h
a
n
g
e
s
 
o
n
 
g
e
n
e
r
i
c
 
d
r
u
g
s
 
i
n
 
e
i
g
h
t
 
E
u
r
o
p
e
a
n
 
c
o
u
n
t
r
i
e
s
,
a
 
2
0
0
8
–
2
0
1
1
P
o
l
i
c
y
 
m
e
a
s
u
r
e
I
m
p
l
e
m
e
n
t
a
t
i
o
n
 
d
a
t
e
 
o
f
 
c
h
a
n
g
e
 
i
n
 
p
o
l
i
c
y
1
s
t
 
h
a
l
f
 
o
f
 
2
0
0
8
2
n
d
 
h
a
l
f
 
o
f
 
2
0
0
8
1
s
t
 
h
a
l
f
 
o
f
 
2
0
0
9
2
n
d
 
h
a
l
f
 
o
f
 
2
0
0
9
1
s
t
 
h
a
l
f
 
o
f
 
 
2
0
1
0
2
n
d
 
h
a
l
f
 
o
f
 
 
2
0
1
0
1
s
t
 
h
a
l
f
 
o
f
 
 
2
0
1
1
2
n
d
 
h
a
l
f
 
o
f
 
 
2
0
1
1
I
N
N
 
p
r
e
s
c
r
i
b
i
n
g
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
E
s
t
o
n
i
a
:
 
c
h
a
n
g
e
 
f
r
o
m
 
o
p
t
i
o
n
a
l
 
t
o
 
c
o
m
p
u
l
s
o
r
y
 
g
e
n
e
r
i
c
 
p
r
e
s
c
r
i
b
i
n
g
S
l
o
v
a
k
i
a
:
 
o
p
t
i
o
n
a
l
 
g
e
n
e
r
i
c
 
p
r
e
s
c
r
i
b
i
n
g
 
i
n
t
r
o
d
u
c
e
d
S
p
a
i
n
:
 
o
p
t
i
o
n
a
l
 
g
e
n
e
r
i
c
 
p
r
e
s
c
r
i
b
i
n
g
 
i
n
t
r
o
d
u
c
e
d
.
 
P
o
r
t
u
g
a
l
:
 
c
o
m
p
u
l
s
o
r
y
 
g
e
n
e
r
i
c
 
p
r
e
s
c
r
i
b
i
n
g
 
s
p
e
c
i
fi
e
d
G
e
n
e
r
i
c
 
s
u
b
s
t
i
t
u
t
i
o
n
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
P
u
b
l
i
c
 
c
a
m
p
a
i
g
n
s
 
a
n
d
 
o
t
h
e
r
 
g
e
n
e
r
i
c
 
p
o
l
i
c
i
e
s
A
u
s
t
r
i
a
:
 
g
e
n
e
r
i
c
s
 
i
n
f
o
r
m
a
t
i
o
n
 
c
a
m
p
a
i
g
n
N
o
n
e
N
o
n
e
N
o
n
e
E
s
t
o
n
i
a
:
 
g
e
n
e
r
i
c
 
c
a
m
p
a
i
g
n
E
s
t
o
n
i
a
:
 
e
-
p
r
e
s
c
r
i
b
i
n
g
 
i
n
t
r
o
d
u
c
e
d
.
 
I
r
e
l
a
n
d
:
 
r
e
b
a
t
e
s
 
f
o
r
 
g
e
n
e
r
i
c
s
 
a
b
o
l
i
s
h
e
d
.
 
P
o
r
t
u
g
a
l
:
 
c
a
m
p
a
i
g
n
 
t
o
 
p
r
o
m
o
t
e
 
r
a
t
i
o
n
a
l
 
m
e
d
i
c
i
n
e
s
 
u
s
e
;
 
d
i
s
p
e
n
s
i
n
g
 
o
f
 
u
n
i
t
 
d
o
s
e
s
 
r
a
t
h
e
r
 
t
h
a
n
 
s
e
a
l
e
d
 
p
a
c
k
a
g
e
s
;
 
p
r
i
c
e
s
 
t
o
 
b
e
 
d
i
s
p
l
a
y
e
d
 
o
n
 
p
a
c
k
a
g
i
n
g
.
 
S
l
o
v
a
k
i
a
:
 
e
s
t
a
b
l
i
s
h
m
e
n
t
 
o
f
 
h
e
a
l
t
h
 
t
e
c
h
n
o
l
o
g
y
 
a
s
s
e
s
s
m
e
n
t
 
i
n
s
t
i
t
u
t
e
.
 
S
p
a
i
n
:
 
n
a
t
i
o
n
a
l
 
g
e
n
e
r
i
c
s
 
c
a
m
p
a
i
g
n
S
p
a
i
n
:
 
u
n
i
t
 
d
o
s
e
 
d
i
s
p
e
n
s
i
n
g
 
i
n
t
r
o
d
u
c
e
d
 
f
o
r
 
f
o
u
r
 
s
u
b
s
t
a
n
c
e
s
P
o
r
t
u
g
a
l
:
 
e
-
p
r
e
s
c
r
i
b
i
n
g
 
i
n
t
r
o
d
u
c
e
d
 
a
n
d
 
o
p
e
n
i
n
g
 
h
o
u
r
s
 
o
f
 
p
h
a
r
m
a
c
i
e
s
 
c
h
a
n
g
e
d
.
 
P
o
r
t
u
g
a
l
:
 
e
n
t
r
y
 
o
f
 
2
5
 
a
c
t
i
v
e
 
g
e
n
e
r
i
c
 
s
u
b
s
t
a
n
c
e
s
 
i
n
t
o
 
t
h
e
 
m
a
r
k
e
t
 
t
o
 
b
e
 
e
x
p
e
d
i
t
e
d
 
s
u
b
j
e
c
t
 
t
o
 
r
e
s
o
l
u
t
i
o
n
 
o
f
 
p
a
t
e
n
t
 
d
i
s
p
u
t
e
s
I
N
N
:
 
i
n
t
e
r
n
a
t
i
o
n
a
l
 
n
o
n
p
r
o
p
r
i
e
t
a
r
y
 
n
a
m
e
.
a
 
 
A
u
s
t
r
i
a
,
 
E
s
t
o
n
i
a
,
 
F
i
n
l
a
n
d
,
 
G
r
e
e
c
e
,
 
I
r
e
l
a
n
d
,
 
P
o
r
t
u
g
a
l
,
 
S
l
o
v
a
k
i
a
 
a
n
d
 
S
p
a
i
n
.